Inizio Ignite

Zuellig pharma collaborates with Taiko on Cleverin in Taiwan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.
- Advertisement -

Building on many years of partnership, Zuellig Pharma Taiwan and Taiko Pharmaceutical Limited have kicked off a new collaboration that will see Zuellig Pharma distribute and promote Cleverin in Taiwan. 

 

Cleverin® is a leading Japanese environmental decontamination technology, and has been listed by the US Centers for Disease Control and Prevention and Occupational Safety and Health Administration as an effective disinfectant for healthcare organization and household use. The brand sells approximately 10 million bottles in Japan every year. 

Zuellig Pharma Taiwan Chief Executive John Chou said: “Cleverin® is an innovative environmental decontaminant technology to prevent infectants spreading at home. We are proud to work with Taiko Pharmaceutical to help them make this technology available in the Taiwan market.” As part of the promotional strategy, Zuellig Pharma Taiwan organized for Taiko Pharmaceutical President Dr. Takashi Shibata to give a presentation at the Greater Taipei Area Hospital and the Densely Populated Organization Infection Control Seminar. 

“Dr. Shibata was invited to speak as an expert in chlorine dioxide gas technology and the experience the company has had in Japan with this technology,” Mr. Chou said. “The events were attended by Minister of Health and Welfare Dr. Lin Tzou-yien, and more than 800 healthcare professionals. It was therefore a great opportunity for us to raise awareness of Taiko Pharmaceutical and its expertise in this category among Taiwan’s medical community.”

Latest stories

Related stories

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Nitrosamine Risk Mitigation in Global Pharma Manufacturing

Nitrosamine risk mitigation in global pharma manufacturing requires proactive control of chemical pathways, excipients, and operational practices to prevent trace-level carcinogenic impurities. Advanced analytics, rigorous risk assessments, and strengthened GMP frameworks are now essential to ensure long-term product safety and regulatory compliance.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »